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Background: This study aims to describe trends in the rate of abdominal aortic aneurysm (AAA) and use of open
surgery repair (OSR) and endovascular aneurysm repair (EVAR) in elderly patients with and without type 2 diabetes
in Spain, 2003–2012.
Methods: We select all patients with a discharge of AAA using national hospital discharge data. Discharges were
grouped by diabetes status: type 2 diabetes and no diabetes. In both groups OSR and EVAR were identified. The
incidence of discharges attributed to AAA were calculated overall and stratified by diabetes status and year. We
calculated length of stay (LOHS) and in-hospital mortality (IHM). Use of OSR and EVAR were calculated stratified by
diabetes status. Multivariate analysis was adjusted by age, sex, year, smoking habit and comorbidity.
Results: From 2003 to 2012, 115,020 discharges with AAA were identified. The mean age was 74.91 years and
16.7% suffered type 2 diabetes. Rates of discharges due to AAA increased significantly in diabetic patients (50.09 in
2003 to 78.23 cases per 100,000 in 2012) and non diabetic subjects (69.24 to 78.66). The incidences were higher
among those without than those with diabetes in all the years studied.
The proportion of patients that underwent EVAR increased for both groups of patients and the open repair
decreased. After multivariate analysis we found that LOHS and IHM have improved over the study period and
diabetic patients had lower IHM than those without diabetes (OR 0.81; 95%CI 0.76-0.85).
Conclusions: Incidence rates were higher in non-diabetic patients. For diabetic and non diabetic patients the use
of EVAR has increased and open repair seems to be decreasing. IHM and LOHS have improved from 2003 to 2012.
Patients with diabetes had significantly lower mortality.
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Diabetes is a risk factor for peripheral, coronary, and
cerebrovascular disease. However different studies have
associated diabetes with the reduced risk of abdominal
aortic aneurysm (AAA) [1-4]. A recent meta-analysis re-
ported that patients with diabetes have a lower preva-
lence of AAA and they show a decreased risk of
developing new AAA or enlarging their AAA compared
with non-diabetics [5].
The primary risk associated with AAA is rupture, which
may occur suddenly and without symptoms and is often
fatal. An estimated 59% to 83% of patients with AAA rup-
ture die before hospitalization and operative mortality (in
hospital or 30-day) is approximately 40%. Almost all
deaths from rupture occur after age 65 years, and most
deaths in women occur after age 80 years [6,7].
Since its introduction in 1991, endovascular aneurism
repair (EVAR) has significantly extended [8]. EVAR is an
alternative to open surgery repair (OSR), especially in
patients for whom open surgery poses a considerable
risk due to coexisting medical conditions, including pa-
tients with diabetes [9]. Whether diabetes is a risk factor
for mortality and morbidity after AAA repair is contro-
versial. In 2005, Leurs et al. have shown that people with
diabetes have a significantly higher early mortality rate
as well as a higher incidence of device-related complica-
tions compared with non-diabetics following endovascular
AAA repair [10]. An increased perioperative morbidity
and mortality risk for people with diabetes undergoing
aortic surgery, however, is not universally accepted. There
have been studies that have shown that diabetes is not
associated with significantly worse major outcomes fol-
lowing AAA repair [11,12]. Indeed, Hughes et al. reported
that following open, elective, infra-renal AAA repair,
diabetes is not associated with an increased risk of
mortality compared with non-diabetics (OR 1.4, 95%CI
0.68-2.71) [13].
The prevalence of AAA in Spain has been reported in
previous investigations [14-18]. However, most studies
included small samples and were conducted on primary
health care centers or hospital services using ultrasonog-
raphy as the diagnosis method. The prevalence observed
for the 65–75 year age group ranged from 3% to 5%
[14-18]. In Spain there is no population based screening
program for AAA and the Medical Societies recommend
screening for AAA with ultrasonography in men aged 65
to 75 years who have ever smoked [16].
To our knowledge, no previous studies have investi-
gated national trends in the use and outcomes of open
and endovascular AAA repair in diabetic and non dia-
betic patients in Spain.
In this study, we used national hospital discharge data to
examine trends in the incidence of AAA among hospital-
ized elderly patients with and without type 2 diabetesbetween 2003 and 2012 in Spain. In particular, we ana-
lyzed trends in the use of open and endovascular AAA re-
pair, patient comorbidities, and in-hospital outcomes such
as in-hospital mortality (IHM) and length of hospital stay
(LOHS).
Methods
This retrospective, observational study was conducted
using the Spanish National Hospital Database (CMBD,
Conjunto Minimo Básico de Datos). This database is
managed by the Spanish Ministry of Health, Social Ser-
vices and Equality and compiles all public and private
hospital data, hence covering more than 95% of hospital
discharges [19]. The CMBD includes patient variables
(sex, date of birth), admission date, discharge date, up to
14 discharge diagnoses, and up to 20 procedures per-
formed during the hospital stay. The Spanish Ministry of
Health, Social Services and Equality sets standards for
record-keeping and performs periodic audits [19]. Data
collected between January 1, 2003 and December 31,
2012 were analyzed.
Disease and procedure criteria were defined according
to the International Classification of Diseases-Ninth Re-
vision, Clinical Modification (ICD-9-CM), which is used
in the Spanish CMBD.
We selected discharges for subjects whose medical diag-
nosis included AAA codes according to the ICD-9-CM:
441.3; 441.4; 441.5 in any diagnosis field. We only included
subjects aged 50 years or over because the very low inci-
dence of AAA is in the population under this age [3].
We identified open AAA repairs and endovascular
AAA repairs using ICD-9-CM procedures codes, 38.44
and 39.71, respectively.
Discharges were grouped by diabetes status as follows:
type 2 diabetes (ICD-9-CM codes: 250.x0; 250.x2) and
no diabetes. Patients with type 1 diabetes (ICD-9-MC
codes: 250.x1; 250.x3) were excluded.
Clinical characteristics included information on overall
comorbidity at the time of diagnosis, which was assessed
by calculating the Charlson comorbidity index (CCI).
The index applies to 17 disease categories, the scores of
which are added to obtain an overall score for each pa-
tient [20]. We divided patients into three categories: low
index, which corresponds to patients with no previously
recorded disease or with one disease category; medium
index, patients with two categories; and high index, pa-
tients with three or more disease categories. To calculate
the CCI we used 16 disease categories, excluding dia-
betes, as described by Thomsen RW et al. [21].
Information on smoking was identified using ICD-9-
CM codes: 305 and V1582.
The mean LOHS and the proportion of patients that
died during the hospital admission (IHM) were also esti-
mated for each year studied.
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database for any missing data on the following vari-
ables: Sex, Date of birth, Admission date, Discharge
date and if the patient died during the hospitalization.
If any of these variables were missing the record was
deleted for the analysis. As all the databases pass a
quality control at the Ministry of Health before are sent
to the investigators we had to discharge under 0.1% of
records.
Statistical analysis
To assess time trends, rates of AAA discharges and
open and endovascular repairs for type 2 diabetes and
non-diabetic patients were calculated in terms of 100,000
inhabitants. We calculated yearly diabetes-specific inci-
dence rates dividing the number of cases per year, sex,
and age group by the corresponding number of people
in that population group, using age- and sex-adjusted
estimated prevalence of diabetes obtained from Na-
tional Health Surveys conducted in 2003/4, 2006/7,
2009/10 and 2011/12 and data from Di@bet.es Study
[22,23]. We also calculated the yearly age- and sex-
specific incidence rates for non-diabetic patients divid-
ing the number of cases per year, sex, and age group by
the corresponding number of people in that population
group (excluding those with type 2 diabetes), according
to data from the Spanish National Institute of Statistics,
as reported on December 31 of each year [24].
A descriptive statistical analysis was performed for all
continuous variables and categories by stratifying dis-
charges for AAA, open and endovascular repairs accord-
ing to diabetes status. Variables are shown as proportions,
means with standard deviations or medians with inter-
quartile ranges (LOHS). Bivariate analyses of variables ac-
cording to year was using χ2 linear trend analysis
(proportions), ANOVA (means) and Kruskall-Wallis test
(medians), as appropriate.
In order to test the time trend in the incidence due to
abdominal aortic aneurysm, we fitted separate Poisson
regression models for patients with and without type 2
diabetes, using year of discharge, sex, age, CCI, smoking
and type of repair as independent variables. A global
model including the same variables and diabetes status
was also conducted to assess the adjusted effect of dia-
betes in the incidence.
For IHM, logistic regression analyses were performed
with mortality as a binary outcome using the same
independent variables for those with and without dia-
betes and for the entire population to assess the influence
of diabetes on IHM. Statistical analyses were per-
formed using Stata version 10.1 (Stata, College Station,
Texas, USA). Statistical significance was set at p < 0.05
(2-tailed).Ethical aspects
Data confidentiality was maintained at all times in ac-
cordance with Spanish legislation. Patient identifiers
were deleted before the database was provided to the au-
thors in order to maintain patient anonymity. It is not
possible to identify patients on individual levels, either
in this article or in the database. Given the anonymous
and mandatory nature of the dataset, it was not neces-
sary to obtain informed consent. The study protocol was
approved by the ethics committee of the Universidad
Rey Juan Carlos.
Results
We identified a total of 115,020 discharges of patients
admitted with AAA in Spain from 2003 to 2012. Patients
with type 2 diabetes accounted for 16.7% of total
(19,232); mean age was 74.75 years (SD, 8.86 years) and
93.3% were men. In patients without diabetes mean age
was 74.95 years (SD, 8.86 years) and 91.9% were men.
Patients with type 2 diabetes had significantly higher
CCI values compared with those without diabetes (72%
vs. 65.9% with two or more coexisting conditions,
respectively).
We found that the proportion of patients who smoked
was 33.6% in patients with type 2 diabetes and 34.3% in
those without diabetes.
Shown in Figure 1 are the cumulative incidences of
discharges for AAA according to age group for men and
women with and without diabetes along the entire study
period (2003–2012). The incidences were significantly
higher among men and women without diabetes aged
70–79 and 80 years or over than in patients with type 2
diabetes.
Table 1 shows the annual hospital discharges rates,
clinical characteristic and outcomes for patients with an
AAA discharge diagnosis according to diabetes status
from 2003 to 2012. The cumulative incidence of dis-
charges due to AAA in patients with diabetes increases
significantly from 50.09 cases per 100,000 inhabitants in
2003 to 78.23 cases in 2012. In patients without diabetes,
the incidence increased significantly from 69.24 cases
per 100,000 inhabitants in 2003 to 78.66 cases in 2012.
The incidences were higher among those without than
those with diabetes in all the years studied.
For both groups studied a significant increase in the
mean age and in the prevalence of smoking was ob-
served along the study period.
The mean LOHS fell from 9 days in 2003 to 7 days in
2012 for either patients with type 2 diabetes and in those
without diabetes (p < 0.05).
Crude IHM remained stable overtime for both groups
compared with patients with type 2 diabetes showing
lower IHM than patients without diabetes in all years
studied.
Figure 1 Incidence of abdominal aortic aneurysm among men and women with and without type 2 diabetes by age group.
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tients who underwent scheduled or unscheduled AAA
repair procedures were recorded in Spain.
Tables 2 and 3 show the annual hospital discharges
rates, clinical characteristic and outcomes for patients
with open and endovascular repair procedures according
to diabetes status from 2003 to 2012.
Over the study period, 13.7% (n = 3,553) of all patients
underwent AAA repair procedures had type 2 diabetes.
There were 15,438 open AAA repair procedures (12.9%
[n = 2,002] in patients with type 2 diabetes) and 10,385
endovascular AAA repair procedures (14.9% [n = 1,551]
in patients with type 2 diabetes).
In patients who underwent an OSR, there was a sig-
nificant male predominance in patients both with and
without diabetes (96.3% and 95%). Mean age was 69.73
years (SD, 7.55 years) in patients with type 2 diabetes and
69.85 years (SD, 7.85 years) in those without diabetes.
Patients with type 2 diabetes who underwent OSR pro-
cedure had significantly higher CCI values compared to
those without diabetes (44.3% vs. 41.8% with two or
more coexisting conditions, respectively).
Among those who underwent OSR, the mean LOHS
was 11 days in patients with type 2 diabetes and 12 days
in those without diabetes. Also, IHM was 13.3% in pa-
tients with type 2 diabetes and 17.1% in patients without
diabetes.
As can be seen in Table 2, among patients with type 2
diabetes who underwent open AAA repair, the incidence
of discharges decreases significantly from 6.7 cases per
100,000 inhabitants in 2003 to 6.41 cases in 2012. In pa-
tients without diabetes, the incidence decreased from
12.28 cases per 100,000 inhabitants in 2003 to 8.18 cases
in 2012 (p < 0.05).We found that the proportion of men with diabetes
who underwent OSR decreased from 98.1% in 2003 to
95.8% in 2012 and the prevalence of those with CCI of
two or more fell from 50% in 2003 and 44. 5% in 2012.
LOHS after OSR decreased significantly over the study
period in both groups of patients (16 days in 2003 vs. 9
days in 2012, in patients with type 2 diabetes and 15 days
in 2003 vs. 10 days in 2012, in those without diabetes).
The IHM among those who underwent an OSR did
not change significantly for those with and without type
2 diabetes. We found that over the entire period, in pa-
tients who underwent an EVAR, the mean age was 73.09
years (SD, 7,39 years) in patients with type 2 diabetes
and 73.51 years (SD, 7,84 years) in those without dia-
betes and there was higher proportion of males undergo-
ing endovascular AAA procedures in both groups
(96.8% in patients with type 2 diabetes and 95% in pa-
tients without diabetes).
In our study, patients with diabetes who underwent an
EVAR procedure had significantly higher CCI values than
those without diabetes (53.5% vs. 47.9% with two or more
comorbidities). In patients with type 2 diabetes, the overall
IHM was 5.9% and in those without diabetes 6.8%; how-
ever the mean LOHS was 7 days in both groups.
As can be seen in Table 3 among patients with type 2
diabetes who underwent an EVAR the incidence of dis-
charges increased significantly from 2.14 cases per 100,000
inhabitants in 2003 to 7.21 cases in 2012. In patients with-
out diabetes, the incidence raised significantly from 4.07
cases per 100,000 inhabitants in 2003 to 7.12 cases in 2012.
Over the 10-year study period, the mean age of pa-
tients with type 2 diabetes who underwent an EVAR in-
creased from 72.88 years (SD, 6.51 years) in 2003 to
73.16 years (SD, 7.65 years) in 2012 (p < 0,05).
Table 1 Incidences, clinical characteristics and outcomes of hospital discharges due to abdominal aortic aneurysm among patients with and without type 2
diabetes in Spain, 2003-2012
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total
No Diabetes
N 8157 8388 8857 9002 9305 9508 10208 10724 10871 10768 95788
Incidence* 69.24 71.2 72.53 71.2 73.6 73.25 76.64 80.51 79.41 78.66 74.80
Age, mean (SD)* 74.05 (8.59) 74.06 (8.61) 74.27 (8.7) 74.44 (8.71) 74.76 (8.73) 75.08 (8.8) 75.35 (8.93) 75.43 (9.08) 75.58 (8.97) 75.88 (9.08) 74.95 (8.86)
Male, n (%)* 7499 (91.93) 7747 (92.36) 8193 (92.5) 8334 (92.58) 8622 (92.66) 8775 (92.29) 9315 (91.25) 9839 (91.75) 9932 (91.36) 9808 (91.08) 88064 (91.94)
CCI 0–1, n (%)* 3083 (37.8) 2998 (35.74) 3166 (35.75) 3280 (36.44) 3286 (35.31) 3181 (33.46) 3342 (32.74) 3467 (32.33) 3468 (31.9) 3387 (31.45) 32658 (34.09)
CCI 2, n (%) 2808 (34.42) 2944 (35.1) 3091 (34.9) 3148 (34.97) 3244 (34.86) 3433 (36.11) 3595 (35.22) 3898 (36.35) 3827 (35.2) 3706 (34.42) 33694 (35.18)
CCI ≥3, n (%) 2266 (27.78) 2446 (29.16) 2600 (29.36) 2574 (28.59) 2775 (29.82) 2894 (30.44) 3271 (32.04) 3359 (31.32) 3576 (32.89) 3675 (34.13) 29436 (30.73)
Smoking* 2615 (32.06) 2789 (33.25) 2960 (33.42) 2891 (32.12) 3082 (33.12) 3214 (33.8) 3554 (34.82) 3836 (35.77) 4043 (37.19) 3869 (35.93) 32853 (34.3)
LOSH, mean (SD)* 9 (12) 9 (11) 8 (11) 8 (10) 8 (10) 8 (10) 8 (9) 7 (9) 7 (8) 7 (8) 8 (10)
IHM, n (%) 996 (12.21) 1019 (12.15) 1046 (11.81) 1041 (11.56) 1087 (11.68) 1081 (11.37) 1149 (11.26) 1183 (11.03) 1212 (11.15) 1234 (11.46) 11048 (11.53)
Diabetes
N 1196 1372 1533 1619 1790 2055 2211 2315 2506 2635 19232
Incidence* 50.09 57.46 61.61 62.54 69.14 72.75 74.68 78.19 74.4 78.23 68.87
Age, mean (SD)* 74.37 (7.75) 73.53 (8.1) 73.96 (8.19) 74.61 (7.92) 74.51 (8.03) 74.71 (8.47) 75.03 (8.36) 74.88 (8.24) 75.38 (8.3) 75.34 (8.32) 74.75 (8.86)
Male, n (%) 1111 (92.89) 1293 (94.24) 1442 (94.06) 1482 (91.54) 1678 (93.74) 1917 (93.28) 2063 (93.31) 2163 (93.43) 2344 (93.54) 2448 (92.9) 17941 (93.29)
CCI 0–1, n (%)* 325 (27.17) 378 (27.55) 468 (30.53) 503 (31.07) 470 (26.26) 573 (27.88) 603 (27.27) 651 (28.12) 721 (28.77) 693 (26.3) 5385 (28.00)
CCI 2, n (%) 456 (38.13) 530 (38.63) 553 (36.07) 580 (35.82) 630 (35.2) 728 (35.43) 824 (37.27) 826 (35.68) 857 (34.2) 939 (35.64) 6923 (36.00)
CCI ≥3, n (%) 415 (34.7) 464 (33.82) 512 (33.4) 536 (33.11) 690 (38.55) 754 (36.69) 784 (35.46) 838 (36.2) 928 (37.03) 1003 (38.06) 6924 (36.00)
Smoking* 379 (31.69) 482 (35.13) 522 (34.05) 518 (32) 569 (31.79) 650 (31.63) 760 (34.37) 774 (33.43) 867 (34.6) 939 (35.64) 6460 (33.59)
LOSH, mean (SD)* 9 (11) 8 (11) 8 (11) 8 (10) 8 (11) 8 (10) 8 (10) 7 (9) 7 (8) 7 (8) 8 (10)
IHM, n (%) 129 (10.79) 137 (9.99) 149 (9.72) 161 (9.94) 172 (9.61) 194 (9.44) 192 (8.68) 201 (8.68) 236 (9.42) 231 (8.77) 1802 (9.37)
N: Number of discharges; Incidence: per 100,000 inhabitants; LOHS: length of stay; IHM: In-hospital mortality; CCI (Charlson Comorbidity Index): Comorbidities included in the Charlson comorbidity index, except diabetes.












Table 2 Incidences, clinical characteristics and outcomes of hospital discharges after open abdominal aortic aneurysm repair among patients with and without
type 2 diabetes in Spain, 2003-2012
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total
No diabetes
N 1447 1431 1458 1462 1365 1332 1329 1315 1177 1120 13436
Incidence* 12,28 12.15 11.94 11.56 10.8 10.26 9.98 9.87 8.6 8.18 10.49
Age, mean (SD) 70.03 (7.62) 69.91 (7.51) 70.02 (7.67) 69.83 (7.72) 69.92 (7.7) 70.04 (7.95) 69.71 (8) 69.52 (8.28) 69.54 (8.03) 69.97 (8.16) 69.85 (7.85)
Male, n (%)* 1377 (95.16) 1379 (96.37) 1407 (96.5) 1401 (95.83) 1292 (94.65) 1268 (95.2) 1240 (93.3) 1247 (94.83) 1094 (92.95) 1057 (94.38) 12762 (94.98)
CCI 0–1, n (%)* 826 (57.08) 773 (54.02) 832 (57.06) 867 (59.3) 811 (59.41) 761 (57.13) 770 (57.94) 762 (57.95) 721 (61.26) 704 (62.86) 7827 (58.25)
CCI 2, n (%) 448 (30.96) 485 (33.89) 446 (30.59) 457 (31.26) 408 (29.89) 430 (32.28) 426 (32.05) 428 (32.55) 343 (29.14) 311 (27.77) 4182 (31.13)
CCI ≥3, n (%) 173 (11.96) 173 (12.09) 180 (12.35) 138 (9.44) 146 (10.7) 141 (10.59) 133 (10.01) 125 (9.51) 113 (9.6) 105 (9.38) 1427 (10.62)
Smoking* 588 (40.64) 600 (41.93) 607 (41.63) 564 (38.58) 537 (39.34) 523 (39.26) 548 (41.23) 575 (43.73) 527 (44.77) 475 (42.41) 5544 (41.26)
LOSH, mean (SD)* 15 (15) 14 (15) 13 (15) 12 (13) 12 (14) 12 (14) 12 (13) 11 (12) 10 (12) 10 (11) 12 (14)
IHM, n (%) 272 (18.8) 259 (18.1) 231 (15.84) 236 (16.14) 241 (17.66) 223 (16.74) 226 (17.01) 219 (16.65) 205 (17.42) 183 (16.34) 2295 (17.08)
Diabetes
N 160 205 180 196 208 203 212 188 234 216 2002
Incidence* 6.7 8.59 7.23 7.57 8.03 7.19 7.16 6.35 6.95 6.41 7.17
Age, mean (SD) 69.87 (6.57) 70.32 (7.27) 70.33 (6.97) 69.72 (7.7) 69.32 (7.55) 69.2 (7.41) 69.36 (7.95) 70.01 (7.4) 70.02 (8.08) 69.31 (8.11) 69.73 (7.55)
Male, n (%) 157 (98.13) 200 (97.56) 173 (96.11) 189 (96.43) 200 (96.15) 194 (95.57) 206 (97.17) 180 (95.74) 221 (94.44) 207 (95.83) 1927 (96.25)
CCI 0–1, n (%) 80 (50) 100 (48.78) 103 (57.22) 111 (56.63) 116 (55.77) 111 (54.68) 119 (56.13) 121 (64.36) 135 (57.69) 120 (55.56) 1116 (55.74)
CCI 2, n (%) 52 (32.5) 73 (35.61) 56 (31.11) 64 (32.65) 69 (33.17) 66 (32.51) 74 (34.91) 53 (28.19) 81 (34.62) 74 (34.26) 662 (33.07)
CCI ≥3, n (%) 28 (17.5) 32 (15.61) 21 (11.6) 21 (10.71) 23 (11.06) 26 (12.81) 19 (8.96) 14 (7.45) 18 (7.69) 22 (10.19) 224 (11.19)
Smoking 73 (45.63) 89 (43.41) 82 (45.56) 76 (38.78) 78 (37.5) 80 (39.41) 103 (48.58) 85 (45.21) 93 (39.74) 103 (47.69) 862 (43.06)
LOSH, mean (SD)* 16 (18.5) 13 (16) 12 (14) 13 (14) 12 (13) 11 (10) 11 (11.5) 11 (10) 9 (10) 9 (7) 11 (12)
IHM, n (%) 19 (11.88) 28 (13.66) 27 (15) 36 (18.37) 24 (11.54) 26 (12.81) 21 (9.91) 21 (11.17) 37 (15.81) 27 (12.5) 266 (13.29)
N: Number of procedures; Incidence: per 100,000 inhabitants; LOHS: length of stay; IHM: In-hospital mortality; CCI (Charlson Comorbidity Index): Comorbidities included in the Charlson comorbidity index, except diabetes.












Table 3 Incidences, clinical characteristics and outcomes of hospital discharges after endovascular abdominal aortic aneurysm repair among patients with and
without type 2 diabetes in Spain, 2003-2012
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total
No diabetes
N 424 479 589 652 766 835 1119 1257 1334 1379 8834
Incidence* 4.07 4.82 5.16 6.06 6.43 8.4 9.44 9.75 10.07 7.12 6.9
Age, mean* (SD) 72.08 (7.97) 73.11 (7.75) 72.55 (8.02) 73.31 (7.51) 73.56 (8.15) 73.58 (7.74) 73.65 (7.94) 73.99 (7.86) 73.85 (7.75) 73.68 (7.7) 73.51 (7.84)
Male, n (%)* 410 (96.7) 458 (95.62) 572 (97.11) 631 (96.78) 725 (94.65) 792 (94.85) 1052 (94.01) 1191 (94.75) 1261 (94.53) 1299 (94.2) 8391 (94.99)
CCI 0–1, n (%) 250 (58.96) 240 (50.1) 279 (47.37) 348 (53.37) 398 (51.96) 417 (49.94) 588 (52.55) 635 (50.52) 718 (53.82) 732 (53.08) 4605 (52.13)
CCI 2, n (%) 131 (30.9) 163 (34.03) 212 (35.99) 216 (33.13) 263 (34.33) 303 (36.29) 383 (34.23) 455 (36.2) 451 (33.81) 453 (32.85) 3030 (34.30)
CCI ≥3, n (%) 43 (10.14) 76 (15.87) 98 (16.64) 88 (13.5) 105 (13.71) 115 (13.77) 148 (13.23) 167 (13.29) 165 (12.37) 194 (14.07) 1190 (13.57)
Smoking* 151 (35.61) 192 (40.08) 222 (37.69) 246 (37.73) 288 (37.6) 346 (41.44) 451 (40.3) 528 (42) 562 (42.13) 611 (44.31) 3597 (40.72)
LOSH, mean (SD)* 8 (10) 8 (9) 8 (10) 8 (7.5) 8 (9) 7 (8) 7 (9) 7 (7) 6 (6) 6 (6) 7 (8)
IHM, n (%) 25 (5.9) 38 (7.93) 40 (6.79) 49 (7.52) 62 (8.09) 59 (7.07) 69 (6.17) 89 (7.08) 87 (6.52) 83 (6.02) 601 (6.80)
Diabetes
N 51 63 86 104 109 166 209 262 258 243 1551
Incidence* 2.14 2.64 3.46 4.02 4.21 5.88 7.06 8.85 7.66 7.21 5.55
Age, mean* (SD) 72.88 (6.51) 72.37 (7.79) 72.36 (7.21) 73.7 (6.61) 72.39 (7.52) 72.82 (7.54) 73.24 (7.23) 72.98 (7.34) 73.69 (7.65) 73.16 (7.65) 73.09 (7.39)
Male, n (%) 49 (96.08) 59 (93.65) 86 103 (99.04) 104 (95.41) 161 (96.99) 203 (97.13) 257 (98.09) 247 (95.74) 233 (95.88) 1502 (96.84)
CCI 0–1, n (%)* 21 (41.18) 21 (33.33) 41 (47.67) 41 (39.42) 47 (43.12) 70 (42.17) 89 (42.58) 138 (52.67) 124 (48.06) 130 (53.5) 722 (46.55)
CCI 2, n (%) 26 (50.98) 30 (47.62) 28 (32.56) 42 (40.38) 38 (34.86) 59 (35.54) 91 (43.54) 95 (36.26) 97 (37.6) 75 (30.86) 581 (37.46)
CCI ≥3, n (%) 4 (7.84) 12 (19.05) 17 (19.77) 21 (20.19) 24 (22.02) 37 (22.29) 29 (13.88) 29 (11.07) 37 (14.34) 38 (15.64) 248 (15.99)
Smoking* 18 (35.29) 33 (52.38) 34 (39.53) 37 (35.58) 34 (31.19) 59 (35.54) 100 (47.85) 120 (45.8) 109 (42.25) 106 (43.62) 650 (41.91)
LOSH, mean (SD) 9 (8) 7 (7) 8 (7) 7 (8) 8 (12) 7 (6) 7 (6) 7 (8) 7 (7) 6 (6) 7 (7)
IHM, n (%) 3 (5.88) 6 (9.52) 3 (3.49) 9 (8.65) 9 (8.26) 11 (6.63) 12 (5.74) 11 (4.2) 15 (5.81) 12 (4.94) 91 (5.87)
N: Number of procedures; Incidence: per 100,000 inhabitants; LOHS: length of stay; IHM: In-hospital mortality; CCI (Charlson Comorbidity Index): Comorbidities included in the Charlson comorbidity index, except diabetes.
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creased significantly from 8 days (SD, 10 days) in 2003
to 6 days (SD, 6 days) in 2012, but remained stable in
those with type 2 diabetes over the period of study
(Table 3). The IHM among those who underwent an
EVAR remained stable for those with and without type 2
diabetes during the 10-year study.
Table 4 summaries the results of multivariate analysis
of trends and factors associated with incidence and IHM
among patients with and without diabetes hospitalized
for AAA. From 2003 to 2012, the adjusted incidence rate
ratio of having a AAA discharge diagnosis in patients
with type 2 diabetes was significant and higher than in
those without diabetes(1.09 95%CI 1.08-1.09 vs. 1.03
95% CI 1.02-1.04).
Incidence rate ratios were significantly greater in older
subjects, especially those age 70–79 years, and patients
with ≥2 comorbidities for those with and without
diabetes.
With regard to IHM, among subjects with diabetes
IHM was significantly greater in women than in men
(OR, 1.38; 95%CI, 1.17-1.65), in older subjects (OR 2.71;
95%CI 2.02-3.64 in ≥80 aged group compared with refer-
ence category 50–59 years) and in those with more co-
morbidities (OR 1.36; 95%CI, 1.18-1.56 for those with 2
comorbidities and OR 2.12; 95%CI, 1.93-2.53 for those
with ≥3 comorbidities). Over the entire period of time
and after adjusting the model for the rest of the vari-
ables, the probability of dying of a diabetic smoker pa-
tient with AAA is 0.65 (95%CI 0.57-0.73) times lower
than for a diabetic non smoker patient.
Those diabetic patients who received an OSR proced-
ure had a 2.52-fold (95%CI 2.06-2.93) higher probability
of dying during their stay than those who did not
undergo this procedure. Time trend analysis showed a
significant decrease in mortality from 2003 to 2012 (OR
0.98 95% CI 0.96-0.99. As can be seen in Table 4 the
same variables were associated to IHM among those
without diabetes.
When we analyzed the entire database, patients with
type 2 diabetes had significantly lower mortality than pa-
tients without diabetes after adjusting for all covariates
(OR, 0.81; 95%CI, 0.76-0.85).
Discussion
Our results reveal that more than 16% of Spanish adults
who suffer AAA have an associated diagnosis of dia-
betes. These results are consistent with those of De
Rango et al. (2012), who showed that 13.6% of patients
admitted to hospital for AAA in Italy had diabetes [25].
Using the Spanish National Hospital Database, we
found that rates of hospitalization for AAA in patients
with and without type 2 diabetes increased significantly
from 2003 to 2012, but incidence rates were higher innon-diabetic patients over the period of study. In Italy,
Sensi et al. indicated that when they focused on elderly
patients (aged 75 years or more) hospitalization rates in-
creased over time and explain this trend as a delayed
clinical onset of illness, resulting from the combined ef-
fect of genetic factors and the decrease of smoking [26].
In US, Mureebe et al. found a significant increase in the
number of hospitalizations for intact AAA from 296 per
100,000 in 1995 to 341 per 100,000 beneficiaries in 2006.
They indicated that AAA rates have increased signifi-
cantly due to elective repair of large aneurysm prevents
subsequent rupture and another potential explanation
for the increase in number of admissions for the diagno-
sis of AAA was that there has been for patients who
have EVAR, and those patients may be inflating the ad-
mission pool of those patients with the diagnosis [27].
After adjusting by age and sex the incidence of hos-
pital discharge with an AAA diagnosis was significantly
lower among men and women with diabetes as com-
pared to non diabetic subjects.
Previous reports based in cross-sectional studies of
AAA screening and case–control studies have shown an
inverse association between diabetes and AAA [3,5,28,29].
In 2015, Shah et al. investigated this evidence from large
prospective cohort studies with 3113 AAA events and
concluded that type 2 diabetes was inversely associated
with AAA (adjusted HR 0.46 95%IC 0.35-0.59) [4].
We found an increase in EVAR procedure rates and
decline in hospital admissions for OSR in patients with
and without type 2 diabetes from 2003 to 2012. Sensi et
al. indicated that EVAR technique became the preferred
method for AAAs since 2008 and the advantage of this
surgical procedure is that it requires shorter hospitaliza-
tions, although is more costly [26].
Our investigation reinforces the well-known fact that
AAA incidence is significantly lower in women than in
men [3]. However, despite having one fifth the number
of AAAs than men, women constitute approximately
one-third of all ruptures and almost as many deaths as
men [30,31]. In our study IHM was significantly greater
in women with than in men with or without diabetes.
Mureebe et al. (2010) found that female gender was as-
sociated with increased risk of death (OR 1.53; CI95%
1.47-1.58) in patients with ruptured AAA and the mor-
tality rate for women was higher by 8.9% for open repair
and higher by 7.1% for EVAR vs. men. These authors
suggest that biologic factors and mechanical properties
of the aorta may contribute to the differences seen be-
tween men and women [32].
In our study, the IHM decreased over time among dia-
betic and non-diabetic patients with a diagnosis of AAA.
However because the number of hospitalizations in-
creased over time, the decreased in mortality rates sug-
gest good quality of care [26].
Table 4 Multivariate analysis of the factors associated with incidence and mortality due to abdominal aortic aneurysm among patients with and without type 2
diabetes in Spain, 2003-2012
Incidence (IRR)* In-hospital mortality (OR)‡
Diabetes No Diabetes Total Diabetes No Diabetes Total
Sex Men 1 1 1 1 1 1
Female 0.08 (0.07-0.09) 0.09 (0.08-0.010) 0.09 (0.08-0.010) 1.38 (1.17-1.65) 1.16 (1.08-1.24) 1.19 (1.12-1.27)
Age groups (years) 50-59 1 1 1 1 1 1
60-69 4.07 (3.78-4.38) 3.69 (3.58-3.80) 3.74 (3.64-3.85) 1.13 (0.83-1.54) 1.09 (0.97-1.23) 1.09 (0.98-1.22)
70-79 9.10 (8.50-9.74) 7.56 (7.35-7.78) 7.79 (7.58-7.99) 1.55 (1.16-2.07) 1.59 (1.42-1.77) 1.58 (1.43-1.75)
≥80 5.93 (5.54-6.37) 5.79 (5.62-5.96) 5.80 (5.65-5.96) 2.71 (2.02-3.64) 2.83 (2.53-3.16) 2.81 (2.53-3.12)
Charlson index 0-1 1 1 1 1 1 1
2 1.29 (1.24-1.34) 1.03 (1.01-1.05) 1.07 (1.05-1.08) 1.36 (1.18-1.56) 1.03 (0.98-1.09) 1.07 (1.02-1.13)
≥3 1.30 (1.26-1.36) 0.91 (0.89-0.93) 0.96 (0.95-0.98) 2.12 (1.93-2.53) 1.68 (1.59-1.77) 1.74 (1.65-1.82)
Smoking No 1 1 1 1 1 1
Yes 0.53 (0.51-0.55) 0.52 (0.51-0.53) 0.53 (0.52-0.54) 0.65 (0.57-0.73) 0.60 (0.57-0.62) 0.60 (0.58-0.63)
Open abdominal aortic aneurysm repair No 1 1 1 1 1 1
Yes 0.13 (0.12-0.14) 0.17 (0.16-0.17) 0.16 (0.15-0.18) 2.52 (2.16-2.93) 2.55 (2.41-2.69) 2.55 (2.42-2.68)
Endovascular aortic aneurysm repair No 1 1 1 1 1 1
Yes 0.10 (0.9-0.101 0.10 (0.9-0.11) 0.10 (0.9-0.12) 0.82 (0.65-1.02) 0.71 (0.65-0.77) 0.72 (0.67-0.78)
Diabetes No NA NA 1 NA NA 1
Yes NA NA 0.20 (0.19-0.21) NA NA 0.81 (0.76-0.85)
Year 1.09 (1.08-1.09) 1.03 (1.02-1.04) 1.04 (1.03-1.05) 0.98 (0.96-0.99) 0.98 (0.97-0.99) 0.98 (0.97-0.99)
*Calculated using multivariate Poisson regression: Incidence Rate Ratios (IRR). ‡ Calculated using logistic regression models: Odds Ratio (OR). The logistic regression multivariate model and Poisson regression model
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mortality than patients without diabetes. One explan-
ation is the presence of diabetes might be an additional
factor to select the best strategy to apply in individual
small AAAs. It has been shown that for patients with
small AAA under surveillance, the risk of death,
aneurysm-related death, and aneurysm rupture are very
low (less than 1% per year) and, therefore, surveillance
has been largely recognized as the best strategy for most
patients [25].
Another explanation could be the “obesity paradox”
[33]. An elevated body mass index (BMI) may be associ-
ated with a decrease in AAA mortality. It is well known
that obesity is much more frequent among those with
than without diabetes. In 2014 Sidloff et al. concluded
that BMI demonstrated a negative linear association
with AAA mortality (P < 0.007) [34]. A recent prospect-
ive study of 18782 persons with diagnosis of AAA in US
concluded that a BMI ≥25 kg/m2 was protective (HR
0.72; 95% CI 0.53-0.98) [35].
Different studies suggest that it is hyperglycemia that
retards aneurysm progression and mortality by AAA.
The Health in Men study reported a negative association
between fasting glucose and aortic diameter in 2859
non-diabetics [36]. Investigators at Standford reported
that hyperglycemia in mice was associated with slower
AAA enlargement, and this effect was diminished by in-
sulin therapy [37].
In our investigation smoking was associated to signifi-
cantly lower in hospital mortality for patients with and
without diabetes.. Kent et al. concluded that a substan-
tial number of women, nonsmokers, and people < 65
with multiple comorbities have a risk of AAA equivalent
to or greater than that of 65-year-old male ever-smokers
[3]. The survival effect, meaning that those who even
suffering diabetes continue smoking are those with less
severe disease and less comorbid conditions, may ex-
plain this association. Also different coding for those
who die in the hospital and those who survive could ex-
plain this association. In any case further studies are ne-
cessary to clarify this association.
We found that patients who received an OSR proced-
ure had higher probability of dying during their stay
than those who did not undergo this procedure. Our re-
sults are consistent with reported in the literature indi-
cating higher 30-day mortality for OSR [38-40].
A recent metaanalysis indicated operative mortality
(30-day/in-hospital) after AAA treatment is increased in
diabetics (OR 1.26 95%CI 1.10-1.44) but IHM after re-
pair in diabetic patients showed no significant higher
risk in these patients (OR 0.97 95%CI 0.63-1.50) [3].
Mureebe et al. (2008) indicated that when they evalu-
ated the effect of EVAR on death, their results agreed
with other studies that found a beneficial effect of EVARin ruptured AAA and concluded that increased usage of
this technology will likely sustain continuous improve-
ment in survival in the future [27].
The strength of our investigation lies in its large sam-
ple size, its 10-year follow-up period and its standardized
methodology, which has previously been used to investi-
gate diabetes and its complications in Spain and else-
where [41,42]. Nevertheless, our study is subject to a
series of limitations. Our data source was the CMBD, an
administrative database that contains discharge data for
Spanish hospitalizations and uses information the phys-
ician has included in the discharge report; therefore, a
limitation important to the analysis of the current data
set is the lack of information about patient anatomy. We
are not able to identify which of these patients had dis-
eased iliac arteries, nor do we know the size of the aneu-
rysms treated. Another significant limitation is the fact
that we have not broken down our diabetic patients into
groups based on therapy used to control blood glucose,
and we were unable to state their blood glucose control
pre- and postoperatively.
The present study also lacks information regarding the
specific effects of diabetic medication on AAA. De
Rango et al. indicated that data supporting the protect-
ive effect of hypoglycemic or other medication against
AAA (e.g., statins, fibrates) are limited and require more
in-depth analysis of their true efficacy [25].
Another limitation of this database is its anonymity
(no identifying items such as clinical history number),
which makes it impossible to detect whether the same
patient was admitted more than once during the same
year. In addition, patients who moved from one hospital
to another would appear twice.
Nevertheless, this dataset, which was introduced in
Spain in 1982, is a mandatory register, and its coverage
is estimated to be greater than 95% [19]. Concerns have
been raised about the accuracy of routinely-collected
datasets; however, these datasets are periodically audited.
Consequently, the quality and validity of our dataset
has been assessed and shown to be useful for health re-
search [43].
Conclusions
Our results show that rates of hospitalization for AAA
in patients with and without type 2 diabetes increased
significantly from 2003 to 2012, but incidence rates were
higher in non-diabetic patients over the period of study
for both sexes and patients aged over 70 years. Patients
with type 2 diabetes had significantly lower mortality
than patients without diabetes. Higher comorbidity and
female gender in patients with AAA are associated with
higher IHM for both groups of patients.
We found a decrease in the use of OSR procedures and
an increase in the use of EVAR procedures in patients with
Lopez-de-Andrés et al. Cardiovascular Diabetology  (2015) 14:48 Page 11 of 12and without type 2 diabetes. Patients who received an
OSR procedure had higher probability of dying during
their stay than those who did not undergo this procedure.
Given the rapid increase in the prevalence of diabetes
and the aging population, these findings emphasize the
need for further improvement in the control of AAA
risk factors in people with diabetes.
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